Apellis Pharmaceuticals, Inc. (BIT:1APLS)

Market Cap	2.08B
Revenue (ttm)	717.81M
Net Income (ttm)	-206.95M
Shares Out	n/a
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	15.33
Day's Range	n/a
52-Week Range	14.60 - 18.08
Beta	n/a
RSI	60.07
Earnings Date	Jul 31, 2025

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem ce...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 710
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1APLS

Financial Performance

In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.

Financial numbers in USD